



MYDECINE INNOVATIONS GROUP ANNOUNCES CHANGES TO BOARD AND MANAGEMENT

Vancouver, British Columbia, March 26, 2025 — Mydecine Innovations Group Inc. (the “**Company**”) (CSE: MYCO) (FSE: ONFO) (OTC: MYCOF) is pleased to announce the appointments of Mr. Peter Field to its board of directors, effective March 18, 2025.

Mr. Field is a seasoned entrepreneur with over 30 years of experience in business development, product innovation, and leadership. Based in Vancouver, he has been involved in ventures leveraging advanced technologies, including an AI-driven vertical farming platform and pharmaceutical commercialization. He has helped build and manage two GMP, USFDA-certified manufacturing facilities and has invested in biotech companies focused on wound care, Alzheimer’s, depression, and cancer biomarkers. More recently, as President of a biotech company, Mr. Field has gained extensive experience in public markets, capital raises, and regulatory compliance, playing a pivotal role in securing funding and guiding corporate governance.

In addition, the Company has appointed Mr. Michael Callas to its Board of Directors, effective March 21, 2025, following the resignation of Mr. Robert Roscow.

Mr. Callas is the founder and CEO of EVOOAI, a company dedicated to preserving human creativity in an AI-driven world. As the former Chief Strategy Officer at Vacuumlabs, he played a key role in launching Daylight, highlighting his commitment to inclusivity in fintech. He has also held leadership positions at EY and Vodafone, driving digital transformation and emerging technology initiatives. Beyond the tech industry, Mr. Callas has served as CEO of StepOne Ventures, fostering innovation and mentoring entrepreneurs, and as Executive Director of Jóvenes con Futuro, connecting Spain’s top young tech talent with startups in Silicon Valley and New York. An internationally acclaimed operatic baritone, he blends artistic and business expertise and holds an academic role at the Istituto Europeo di Design. Recognized as a “Tech Tastemaker” by *Details Magazine*, he continues to shape the tech industry through mentorship, education, and creative vision.

The Company also announces the resignation of Mr. Damon Michaels as its Chief Operating Officer of the Company, effective January 22, 2025.

The Company extends its sincere appreciation to Mr. Roscow and Mr. Michaels for their valuable contributions and wishes them success in their future endeavors.

On behalf of the Board of Directors,

MYDECINE INNOVATIONS GROUP INC.

Joshua Bartch

Chief Executive Officer

Email: contact@mydecineinc.com

Phone: +1 (888) 871 - 3936

About Mydecine Innovations Group Inc.

Mydecine Innovations Group™ is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Mydecine's dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the Company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Mydecine's approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with worldclass scientific and regulatory expertise.

Learn more at: <https://www.mydecine.com/> and follow the company on Twitter, LinkedIn, YouTube, and Instagram.

Forward-looking Information Statement

This news release may contain certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian and United States securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, “expect”, “target”, “plan”, “forecast”, “may”, “schedule” and other similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to the anticipated timing for the filing of the Annual Filings, and other factors or information. Such statements represent the Company’s current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations

NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.